{"parse":{"title":"TB Alliance","pageid":5106067,"revid":840537495,"text":{"*":"<div class=\"mw-parser-output\"><table class=\"plainlinks metadata ambox ambox-content ambox-Refimprove\" role=\"presentation\"><tbody><tr><td class=\"mbox-image\"><div style=\"width:52px\"><a href=\"/wiki/File:Question_book-new.svg\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/50px-Question_book-new.svg.png\" width=\"50\" height=\"39\" srcset=\"//upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/75px-Question_book-new.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/100px-Question_book-new.svg.png 2x\" data-file-width=\"512\" data-file-height=\"399\" /></a></div></td><td class=\"mbox-text\"><div class=\"mbox-text-span\">This article <b>needs additional citations for <a href=\"/wiki/Wikipedia:Verifiability\" title=\"Wikipedia:Verifiability\">verification</a></b>.<span class=\"hide-when-compact\"> Please help <a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=TB_Alliance&amp;action=edit\">improve this article</a> by <a href=\"/wiki/Help:Introduction_to_referencing_with_Wiki_Markup/1\" title=\"Help:Introduction to referencing with Wiki Markup/1\">adding citations to reliable sources</a>. Unsourced material may be challenged and removed.</span>  <small><i>(February 2017)</i></small><small class=\"hide-when-compact\"><i> (<a href=\"/wiki/Help:Maintenance_template_removal\" title=\"Help:Maintenance template removal\">Learn how and when to remove this template message</a>)</i></small></div></td></tr></tbody></table>\n<table class=\"infobox vcard\" style=\"width:22em\"><caption class=\"fn org\">The Global Alliance for TB Drug Development</caption><tbody><tr><td colspan=\"2\" style=\"text-align:center\">\n<a href=\"/wiki/File:TBA_logo_rev_2008lg_RGB.jpg\" class=\"image\"><img alt=\"TBA logo rev 2008lg RGB.jpg\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/9/91/TBA_logo_rev_2008lg_RGB.jpg/220px-TBA_logo_rev_2008lg_RGB.jpg\" width=\"220\" height=\"33\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/9/91/TBA_logo_rev_2008lg_RGB.jpg/330px-TBA_logo_rev_2008lg_RGB.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/9/91/TBA_logo_rev_2008lg_RGB.jpg/440px-TBA_logo_rev_2008lg_RGB.jpg 2x\" data-file-width=\"3000\" data-file-height=\"455\" /></a></td></tr><tr><th scope=\"row\" style=\"padding-right:0.6em;\">Abbreviation</th><td class=\"nickname\">\nTB Alliance</td></tr><tr><th scope=\"row\" style=\"padding-right:0.6em;\">Established</th><td class=\"note\">\nFebruary 2000</td></tr><tr><th scope=\"row\" style=\"padding-right:0.6em;\">Type</th><td>\n<a href=\"/wiki/Nonprofit\" class=\"mw-redirect\" title=\"Nonprofit\">Nonprofit</a></td></tr><tr><th scope=\"row\" style=\"padding-right:0.6em;\">Legal status</th><td>\nActive</td></tr><tr><th scope=\"row\" style=\"padding-right:0.6em;\">Headquarters</th><td>\n<a href=\"/wiki/New_York_City\" title=\"New York City\">New York City</a>, <a href=\"/wiki/Pretoria\" title=\"Pretoria\">Pretoria</a></td></tr><tr><th scope=\"row\" style=\"padding-right:0.6em;\"><div style=\"padding:0.1em 0;line-height:1.2em;\">Chief Executive Officer</div></th><td>\nMel Spigelman</td></tr><tr><th scope=\"row\" style=\"padding-right:0.6em;\">Website</th><td>\n<span class=\"url\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.tballiance.org/\">www<wbr />.tballiance<wbr />.org</a></span></td></tr></tbody></table>\n<p><b>The Global Alliance for TB Drug Development</b> <i>(</i><b>TB Alliance</b>) is a not-for-profit product development partnership dedicated to the discovery and development of new, faster-acting and affordable <a href=\"/wiki/Tuberculosis\" title=\"Tuberculosis\">tuberculosis</a> medicines. Since its inception in 2000, TB Alliance has worked to grow the field of available treatments for TB and now manages the largest <a href=\"/wiki/Drug_pipeline\" title=\"Drug pipeline\">pipeline</a> of new TB drugs in history.<sup id=\"cite_ref-1\" class=\"reference\"><a href=\"#cite_note-1\">&#91;1&#93;</a></sup> It was founded in <a href=\"/wiki/Cape_Town\" title=\"Cape Town\">Cape Town</a>, South Africa, and has since expanded. It is headquartered in <a href=\"/wiki/New_York_City\" title=\"New York City\">New York City</a> and has a regional office in <a href=\"/wiki/Pretoria\" title=\"Pretoria\">Pretoria</a>.<sup id=\"cite_ref-2\" class=\"reference\"><a href=\"#cite_note-2\">&#91;2&#93;</a></sup>\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#Background\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">Background</span></a></li>\n<li class=\"toclevel-1 tocsection-2\"><a href=\"#History\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">History</span></a></li>\n<li class=\"toclevel-1 tocsection-3\"><a href=\"#Program\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Program</span></a></li>\n<li class=\"toclevel-1 tocsection-4\"><a href=\"#Adverse_effects_and_patient_compliance\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">Adverse effects and patient compliance</span></a></li>\n<li class=\"toclevel-1 tocsection-5\"><a href=\"#Drug_resistance\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">Drug resistance</span></a></li>\n<li class=\"toclevel-1 tocsection-6\"><a href=\"#Investigational_New_Drugs\"><span class=\"tocnumber\">6</span> <span class=\"toctext\">Investigational New Drugs</span></a></li>\n<li class=\"toclevel-1 tocsection-7\"><a href=\"#Donors\"><span class=\"tocnumber\">7</span> <span class=\"toctext\">Donors</span></a></li>\n<li class=\"toclevel-1 tocsection-8\"><a href=\"#References\"><span class=\"tocnumber\">8</span> <span class=\"toctext\">References</span></a></li>\n<li class=\"toclevel-1 tocsection-9\"><a href=\"#External_links\"><span class=\"tocnumber\">9</span> <span class=\"toctext\">External links</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"Background\">Background</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=TB_Alliance&amp;action=edit&amp;section=1\" title=\"Edit section: Background\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p><a href=\"/wiki/Tuberculosis\" title=\"Tuberculosis\">Tuberculosis</a> infects one third of the world\u2019s population,<sup id=\"cite_ref-3\" class=\"reference\"><a href=\"#cite_note-3\">&#91;3&#93;</a></sup> kills approximately 1.5 million people each year,<sup id=\"cite_ref-4\" class=\"reference\"><a href=\"#cite_note-4\">&#91;4&#93;</a></sup> and costs the global economy $16 billion annually. However, research and development for new TB drugs came to a virtual standstill after the 1960s. Today, a four drug combination therapy exists, but it takes six months or more to be effective. This requires a degree of monitoring (See <a href=\"/wiki/Tuberculosis_treatment#Treatment_monitoring_and_DOTS\" class=\"mw-redirect\" title=\"Tuberculosis treatment\">Direct Observational Therapy, Shortcourse</a>) beyond the capacity of the health infrastructure in many countries; adequate TB treatment is available to less than half of the most infectious cases. This can inhibit control of the disease and fuel the rise of <a href=\"/wiki/Drug_resistance\" title=\"Drug resistance\">drug resistance</a>. TB is also the number one killer of <a href=\"/wiki/AIDS\" class=\"mw-redirect\" title=\"AIDS\">AIDS</a> patients, but it is generally agreed that current TB treatments do not work well with the <a href=\"/wiki/Antiretroviral_drugs\" class=\"mw-redirect\" title=\"Antiretroviral drugs\">antiretroviral drugs</a> used to treat HIV.\n</p><p>The TB drug market lacks sufficient financial incentives to stimulate a single private <a href=\"/wiki/Pharmaceutical_company\" class=\"mw-redirect\" title=\"Pharmaceutical company\">pharmaceutical company</a> to invest in the new research required to sustain a treatment pipeline. The TB <a href=\"/wiki/Epidemic\" title=\"Epidemic\">epidemic</a> is concentrated in developing countries where drugs must be low in cost to remain accessible. It does not generate the kind of revenue streams that private companies usually deem necessary to justify the research costs and strategic risks involved in pharmaceuticals. The TB Alliance was designed to be the primary instrument to fill this vacuum and to ensure that new anti-TB drugs are affordable and accessible in endemic countries.\n</p>\n<h2><span class=\"mw-headline\" id=\"History\">History</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=TB_Alliance&amp;action=edit&amp;section=2\" title=\"Edit section: History\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The TB Alliance was conceived at a February 2000 meeting in <a href=\"/wiki/Cape_Town\" title=\"Cape Town\">Cape Town</a>, <a href=\"/wiki/South_Africa\" title=\"South Africa\">South Africa</a>, where 120 representatives from academia, industry, major government agencies, non-governmental organizations and donors gathered to discuss the problems of tuberculosis treatment. Participants stressed the need for faster-acting, novel TB drugs and highlighted the scientific opportunities involved. The resulting \"Declaration of Cape Town\"<sup id=\"cite_ref-5\" class=\"reference\"><a href=\"#cite_note-5\">&#91;5&#93;</a></sup> provided a road map for TB drug development and outlined the need for creation of the TB Alliance.  <a href=\"/wiki/Maria_Freire\" title=\"Maria Freire\">Maria Freire</a> was appointed as the first Chief Executive Officer and President in 2001 and served in that capacity until 2008, when she left the TB Alliance to become President of the <a href=\"/wiki/Lasker_Foundation\" class=\"mw-redirect\" title=\"Lasker Foundation\">Lasker Foundation</a>.   The current CEO and President is Melvin Spigelman.<sup id=\"cite_ref-6\" class=\"reference\"><a href=\"#cite_note-6\">&#91;6&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Program\">Program</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=TB_Alliance&amp;action=edit&amp;section=3\" title=\"Edit section: Program\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The TB Alliance is a <a href=\"/wiki/Non-profit\" class=\"mw-redirect\" title=\"Non-profit\">non-profit</a> <a href=\"/wiki/Public-private_partnership\" class=\"mw-redirect\" title=\"Public-private partnership\">public-private partnership</a>. It operates like a virtual <a href=\"/wiki/Biotechnology\" title=\"Biotechnology\">biotechnology</a> firm, collaborating with research institutions and pharmaceutical companies so that risks and incentives are shared.  While retaining management oversight of its drug development projects, the TB Alliance out-sources the development of potential drugs to public and private partners, providing funding and scientific guidance. Depending on the project, the TB Alliance either co-invests and co-develops a project, funds and manages it directly, or in-licenses the <a href=\"/wiki/Technology\" title=\"Technology\">technology</a> or <a href=\"/wiki/Intellectual_property\" title=\"Intellectual property\">intellectual property</a> involved. Project diversity is a stated goal, with potentials compounds selected from a variety of <a href=\"/w/index.php?title=Chemical_classes&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Chemical classes (page does not exist)\">chemical classes</a>, with a wide range of targets within the TB organism, <i><a href=\"/wiki/Mycobacterium_tuberculosis\" title=\"Mycobacterium tuberculosis\">Mycobacterium tuberculosis</a></i>.\n</p><p>In January 2009, the TB Alliance had 16 drug projects underway, either in either discovery or clinical or phase. Part of the TB Alliance\u2019s stated mission is to ensure that any new treatments are affordable and accessible in the <a href=\"/wiki/Developing_world\" class=\"mw-redirect\" title=\"Developing world\">developing world</a>, and that they are adopted as soon as they become available. Pricing terms are included in all licensing contracts and end products are designed to be easy to take. The TB Alliance also collaborates with national and international partners, working to ensure that new therapies are adopted and accessible to <a href=\"/wiki/Healthcare_provider\" class=\"mw-redirect\" title=\"Healthcare provider\">healthcare providers</a> and patients via local channels.\n</p>\n<h2><span class=\"mw-headline\" id=\"Adverse_effects_and_patient_compliance\">Adverse effects and patient compliance</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=TB_Alliance&amp;action=edit&amp;section=4\" title=\"Edit section: Adverse effects and patient compliance\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Some anti-tuberculosis agents are known to have some side effects, which limits their use for mono-therapies only. This poses a limitation for their use in combination therapy, for overcoming drug resistance. Also, some of the side effects may lead to a low level of compliance by the patient, i.e. not completing the full course of treatment. This creates conditions within the patient that enable drug resistance to arise or even to become prevalent. In view of such situations it is often recommended that novel anti-tuberculosis agents need to be discovered and developed.\n</p>\n<h2><span class=\"mw-headline\" id=\"Drug_resistance\">Drug resistance</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=TB_Alliance&amp;action=edit&amp;section=5\" title=\"Edit section: Drug resistance\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Drug resistance occurs for several reasons, often as a natural consequence of gene mutations and selection, as a consequence of drug-efflux mechanisms, or due to drug modifying enzymes. Under conditions of medical treatment, mutants that are resistant to the drug may escape the drug's action, survive and multiply further. This is one of the reasons why combination therapies are often essential for treating tuberculosis infections and most infectious diseases. At the present time, three of even four tuberculosis drugs are given as a combination therapy, over an extended period of time, though patient compliance and side effects continue to be a medical issue. Some strains of the tuberculosis pathogen are resistant to all three or four tuberculosis drugs. In view of the contagious nature of tuberculosis, especially among persons with weak immunity, drug resistance is considered to be a serious public health issue.\n</p>\n<h2><span class=\"mw-headline\" id=\"Investigational_New_Drugs\">Investigational New Drugs</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=TB_Alliance&amp;action=edit&amp;section=6\" title=\"Edit section: Investigational New Drugs\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Investigational new drugs (IND) are clinical candidates that are safe and efficacious in the animal models of infection. Usually, these are new chemical entities (NCE) with a novel mechanism of action. Investigational new drugs have to be approved by the national or international medical regulatory authorities, for clinical testing and development in humans.\n</p><p>IND's are usually discovered and developed to overcome the limitations of drugs that are or have been in clinical use.\n</p>\n<h2><span class=\"mw-headline\" id=\"Donors\">Donors</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=TB_Alliance&amp;action=edit&amp;section=7\" title=\"Edit section: Donors\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The TB Alliance has a diverse set of global partnerships with both public and private sector donors that fund the company\u2019s work. The organization operates with the support of:<sup id=\"cite_ref-7\" class=\"reference\"><a href=\"#cite_note-7\">&#91;7&#93;</a></sup>\n</p>\n<ul><li>Australian Aid (AusAID)</li>\n<li><a href=\"/wiki/Bill_%26_Melinda_Gates_Foundation\" title=\"Bill &amp; Melinda Gates Foundation\">Bill &amp; Melinda Gates Foundation</a></li>\n<li><a href=\"/wiki/Ministry_of_Foreign_Affairs_(Netherlands)\" title=\"Ministry of Foreign Affairs (Netherlands)\">Dutch Ministry of Foreign Affairs</a> (DGIS)</li>\n<li><a href=\"/wiki/Federal_Ministry_of_Education_and_Research_(Germany)\" title=\"Federal Ministry of Education and Research (Germany)\">Federal Ministry of Education and Research</a></li>\n<li><a href=\"/wiki/Global_Health_Innovative_Technology_Fund_(GHIT)\" title=\"Global Health Innovative Technology Fund (GHIT)\">Global Health Innovative Technology (GHIT) Fund</a></li>\n<li>Indonesia Health Fund</li>\n<li><a href=\"/wiki/Irish_Aid\" title=\"Irish Aid\">Irish Aid</a></li>\n<li><a href=\"/wiki/Department_for_International_Development\" title=\"Department for International Development\">UK Aid</a></li>\n<li><a href=\"/wiki/Department_of_Health_and_Social_Care\" title=\"Department of Health and Social Care\">UK Department of Health</a></li>\n<li><a href=\"/wiki/United_States_Agency_for_International_Development\" title=\"United States Agency for International Development\">United States Agency for International Development</a> (USAID)</li>\n<li><a href=\"/wiki/Food_and_Drug_Administration\" title=\"Food and Drug Administration\">United States Food and Drug Administration</a> (FDA)</li></ul>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=TB_Alliance&amp;action=edit&amp;section=8\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist\" style=\"list-style-type: decimal;\">\n<div class=\"mw-references-wrap\"><ol class=\"references\">\n<li id=\"cite_note-1\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-1\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.tballiance.org/portfolio\">\"Clinical Portfolio | TB Alliance\"</a>. <i>www.tballiance.org</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2017-06-20</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.tballiance.org&amp;rft.atitle=Clinical+Portfolio+%7C+TB+Alliance&amp;rft_id=https%3A%2F%2Fwww.tballiance.org%2Fportfolio&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATB+Alliance\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-2\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-2\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.tballiance.org/annualreport2016/\">\"Home | TB Alliance 2016 Annual Report\"</a>. <i>TB Alliance 2016 Annual Report</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2017-06-20</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=TB+Alliance+2016+Annual+Report&amp;rft.atitle=Home+%7C+TB+Alliance+2016+Annual+Report&amp;rft_id=http%3A%2F%2Fwww.tballiance.org%2Fannualreport2016%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATB+Alliance\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-3\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-3\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cdc.gov/tb/statistics/\">\"Tuberculosis Data and Statistics\"</a>. <i>www.cdc.gov</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2 May</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cdc.gov&amp;rft.atitle=Tuberculosis+Data+and+Statistics&amp;rft_id=https%3A%2F%2Fwww.cdc.gov%2Ftb%2Fstatistics%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATB+Alliance\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-4\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-4\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cdc.gov/tb/statistics/\">\"Tuberculosis Data and Statistics\"</a>. <i>www.cdc.gov</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2 May</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cdc.gov&amp;rft.atitle=Tuberculosis+Data+and+Statistics&amp;rft_id=https%3A%2F%2Fwww.cdc.gov%2Ftb%2Fstatistics%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATB+Alliance\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-5\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.tballiance.org/downloads/publications/CapeTownDeclaration.pdf\">\"The Cape Town Declaration of the Working Alliance for TB Drug Development\"</a> <span style=\"font-size:85%;\">(PDF)</span>. <i>www.tballiance.org</i>. Cape Town, South Africa. February 8, 2000.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.tballiance.org&amp;rft.atitle=The+Cape+Town+Declaration+of+the+Working+Alliance+for+TB+Drug+Development&amp;rft.date=2000-02-08&amp;rft_id=http%3A%2F%2Fwww.tballiance.org%2Fdownloads%2Fpublications%2FCapeTownDeclaration.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATB+Alliance\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-6\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-6\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.tballiance.org/news/global-alliance-tb-drug-development-appoints-respected-scientist-and-director-rd-new-chief\">\"Global Alliance for TB Drug Development Appoints Respected Scientist and Director of R&amp;D as New Chief Executive\"</a>. <i>www.tballiance.org</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">9 October</span> 2008</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.tballiance.org&amp;rft.atitle=Global+Alliance+for+TB+Drug+Development+Appoints+Respected+Scientist+and+Director+of+R%26D+as+New+Chief+Executive&amp;rft_id=http%3A%2F%2Fwww.tballiance.org%2Fnews%2Fglobal-alliance-tb-drug-development-appoints-respected-scientist-and-director-rd-new-chief&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATB+Alliance\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-7\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.tballiance.org/about/donors\">\"Donors\"</a>. <i>TB Alliance</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2017-06-20</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=TB+Alliance&amp;rft.atitle=Donors&amp;rft_id=https%3A%2F%2Fwww.tballiance.org%2Fabout%2Fdonors&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ATB+Alliance\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div></div>\n<h2><span class=\"mw-headline\" id=\"External_links\">External links</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=TB_Alliance&amp;action=edit&amp;section=9\" title=\"Edit section: External links\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.tballiance.org/\">The Global Alliance for TB Drug Development</a></li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.stoptb.org/\">The Stop TB Partnership</a></li>\n<li><a href=\"/wiki/International_Labour_Organization\" title=\"International Labour Organization\">International Labour Organization</a></li>\n<li><a href=\"/wiki/European_Bioinformatics_Institute\" title=\"European Bioinformatics Institute\">European Bioinformatics Institute</a></li>\n<li><a href=\"/wiki/European_Medicines_Agency\" title=\"European Medicines Agency\">European Medicines Agency</a></li>\n<li><a href=\"/wiki/Food_and_Drug_Administration\" title=\"Food and Drug Administration\">Food and Drug Administration</a></li>\n<li><a href=\"/wiki/Nitroimidazole\" title=\"Nitroimidazole\">Nitroimidazole</a></li>\n<li><a href=\"/wiki/Pyrazinamide\" title=\"Pyrazinamide\">Pyrazinamide</a></li></ul>\n\n<!-- \nNewPP limit report\nParsed by mw1273\nCached time: 20180908205437\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.232 seconds\nReal time usage: 0.300 seconds\nPreprocessor visited node count: 1165/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 16790/2097152 bytes\nTemplate argument size: 518/2097152 bytes\nHighest expansion depth: 9/40\nExpensive parser function count: 1/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 6580/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.109/10.000 seconds\nLua memory usage: 3.61 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  247.237      1 -total\n 38.51%   95.215      1 Template:Infobox_organization\n 36.00%   89.008      1 Template:Reflist\n 30.11%   74.445      1 Template:Infobox\n 27.47%   67.923      7 Template:Cite_web\n 23.28%   57.553      1 Template:Refimprove\n 14.60%   36.098      1 Template:Ambox\n  8.16%   20.180      2 Template:Unbulleted_list\n  4.14%   10.245      4 Template:Comma_separated_entries\n  3.61%    8.934      4 Template:If_empty\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:5106067-0!canonical and timestamp 20180908205437 and revision id 840537495\n -->\n</div>"},"langlinks":[],"categories":[{"sortkey":"","hidden":"","*":"Articles_needing_additional_references_from_February_2017"},{"sortkey":"","hidden":"","*":"All_articles_needing_additional_references"},{"sortkey":"","*":"Tuberculosis_organizations"},{"sortkey":"","*":"International_medical_and_health_organizations"}],"links":[{"ns":14,"exists":"","*":"Category:Articles needing additional references from February 2017"},{"ns":0,"exists":"","*":"AIDS"},{"ns":0,"exists":"","*":"Antiretroviral drugs"},{"ns":0,"exists":"","*":"Bill & Melinda Gates Foundation"},{"ns":0,"exists":"","*":"Biotechnology"},{"ns":0,"exists":"","*":"Cape Town"},{"ns":0,"exists":"","*":"Department for International Development"},{"ns":0,"exists":"","*":"Department of Health and Social Care"},{"ns":0,"exists":"","*":"Developing world"},{"ns":0,"exists":"","*":"Drug pipeline"},{"ns":0,"exists":"","*":"Drug resistance"},{"ns":0,"exists":"","*":"Epidemic"},{"ns":0,"exists":"","*":"European Bioinformatics Institute"},{"ns":0,"exists":"","*":"European Medicines Agency"},{"ns":0,"exists":"","*":"Federal Ministry of Education and Research (Germany)"},{"ns":0,"exists":"","*":"Food and Drug Administration"},{"ns":0,"exists":"","*":"Global Health Innovative Technology Fund (GHIT)"},{"ns":0,"exists":"","*":"Healthcare provider"},{"ns":0,"exists":"","*":"Intellectual property"},{"ns":0,"exists":"","*":"International Labour Organization"},{"ns":0,"exists":"","*":"Irish Aid"},{"ns":0,"exists":"","*":"Lasker Foundation"},{"ns":0,"exists":"","*":"Maria Freire"},{"ns":0,"exists":"","*":"Ministry of Foreign Affairs (Netherlands)"},{"ns":0,"exists":"","*":"Mycobacterium tuberculosis"},{"ns":0,"exists":"","*":"New York City"},{"ns":0,"exists":"","*":"Nitroimidazole"},{"ns":0,"exists":"","*":"Non-profit"},{"ns":0,"exists":"","*":"Nonprofit"},{"ns":0,"exists":"","*":"Pharmaceutical company"},{"ns":0,"exists":"","*":"Pretoria"},{"ns":0,"exists":"","*":"Public-private partnership"},{"ns":0,"exists":"","*":"Pyrazinamide"},{"ns":0,"exists":"","*":"South Africa"},{"ns":0,"exists":"","*":"Technology"},{"ns":0,"exists":"","*":"Tuberculosis"},{"ns":0,"exists":"","*":"Tuberculosis treatment"},{"ns":0,"exists":"","*":"United States Agency for International Development"},{"ns":0,"*":"Chemical classes"},{"ns":4,"exists":"","*":"Wikipedia:Verifiability"},{"ns":12,"exists":"","*":"Help:Introduction to referencing with Wiki Markup/1"},{"ns":12,"exists":"","*":"Help:Maintenance template removal"}],"templates":[{"ns":10,"exists":"","*":"Template:Refimprove"},{"ns":10,"exists":"","*":"Template:More citations needed"},{"ns":10,"exists":"","*":"Template:Ambox"},{"ns":10,"exists":"","*":"Template:Infobox organization"},{"ns":10,"exists":"","*":"Template:Infobox"},{"ns":10,"exists":"","*":"Template:If empty"},{"ns":10,"exists":"","*":"Template:Unbulleted list"},{"ns":10,"exists":"","*":"Template:Comma separated entries"},{"ns":10,"exists":"","*":"Template:Longitem"},{"ns":10,"exists":"","*":"Template:URL"},{"ns":10,"exists":"","*":"Template:Template other"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Cite web"},{"ns":828,"exists":"","*":"Module:Unsubst"},{"ns":828,"exists":"","*":"Module:Message box"},{"ns":828,"exists":"","*":"Module:No globals"},{"ns":828,"exists":"","*":"Module:Yesno"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:Message box/configuration"},{"ns":828,"exists":"","*":"Module:Category handler"},{"ns":828,"exists":"","*":"Module:Category handler/data"},{"ns":828,"exists":"","*":"Module:Category handler/config"},{"ns":828,"exists":"","*":"Module:Category handler/shared"},{"ns":828,"exists":"","*":"Module:Category handler/blacklist"},{"ns":828,"exists":"","*":"Module:Namespace detect/data"},{"ns":828,"exists":"","*":"Module:Namespace detect/config"},{"ns":828,"exists":"","*":"Module:Infobox"},{"ns":828,"exists":"","*":"Module:Navbar"},{"ns":828,"exists":"","*":"Module:InfoboxImage"},{"ns":828,"exists":"","*":"Module:If empty"},{"ns":828,"exists":"","*":"Module:List"},{"ns":828,"exists":"","*":"Module:TableTools"},{"ns":828,"exists":"","*":"Module:Separated entries"},{"ns":828,"exists":"","*":"Module:URL"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"}],"images":["Question_book-new.svg","TBA_logo_rev_2008lg_RGB.jpg"],"externallinks":["https://www.tballiance.org/portfolio","http://www.tballiance.org/annualreport2016/","https://www.cdc.gov/tb/statistics/","http://www.tballiance.org/downloads/publications/CapeTownDeclaration.pdf","http://www.tballiance.org/news/global-alliance-tb-drug-development-appoints-respected-scientist-and-director-rd-new-chief","https://www.tballiance.org/about/donors","https://www.tballiance.org/","http://www.tballiance.org/","http://www.stoptb.org/"],"sections":[{"toclevel":1,"level":"2","line":"Background","number":"1","index":"1","fromtitle":"TB_Alliance","byteoffset":1504,"anchor":"Background"},{"toclevel":1,"level":"2","line":"History","number":"2","index":"2","fromtitle":"TB_Alliance","byteoffset":3359,"anchor":"History"},{"toclevel":1,"level":"2","line":"Program","number":"3","index":"3","fromtitle":"TB_Alliance","byteoffset":4752,"anchor":"Program"},{"toclevel":1,"level":"2","line":"Adverse effects and patient compliance","number":"4","index":"4","fromtitle":"TB_Alliance","byteoffset":6213,"anchor":"Adverse_effects_and_patient_compliance"},{"toclevel":1,"level":"2","line":"Drug resistance","number":"5","index":"5","fromtitle":"TB_Alliance","byteoffset":6835,"anchor":"Drug_resistance"},{"toclevel":1,"level":"2","line":"Investigational New Drugs","number":"6","index":"6","fromtitle":"TB_Alliance","byteoffset":7783,"anchor":"Investigational_New_Drugs"},{"toclevel":1,"level":"2","line":"Donors","number":"7","index":"7","fromtitle":"TB_Alliance","byteoffset":8296,"anchor":"Donors"},{"toclevel":1,"level":"2","line":"References","number":"8","index":"8","fromtitle":"TB_Alliance","byteoffset":9289,"anchor":"References"},{"toclevel":1,"level":"2","line":"External links","number":"9","index":"9","fromtitle":"TB_Alliance","byteoffset":9317,"anchor":"External_links"}],"parsewarnings":[],"displaytitle":"TB Alliance","iwlinks":[],"properties":[{"name":"wikibase_item","*":"Q7669583"}]}}